

The background of the top half of the page features a grayscale image of a complex antibody protein structure. Overlaid on this are several white, five-pointed stars arranged in a circular pattern, reminiscent of the European Union flag. The text is positioned in the lower-left area of this section.

FCF Fox Corporate Finance | FCF Healthcare & Life Sciences  
**Healthcare & Life Sciences Venture Capital Monitor – Europe**

*October 2023*

*Antibody*

**FCF HEALTHCARE & LIFE SCIENCES  
OVERVIEW**



## Overview



### Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



### Focus Areas

FCF advises on the following transaction types:



**FCF Healthcare & Life Sciences**  
*advises leading HC & LS companies in Europe in financing transactions*

*Over EUR 2bn Healthcare & Life Sciences transaction volume*  
*(Professionals and Advisors)*

*Healthcare & Life Sciences Team of >12*

*Over 100 years in aggregated Healthcare & Life Sciences experience*

*Access to > 1,500 international investors*

**Company Valuation**  
*in partnership with BioScience Valuation GmbH*

**China Licensing**  
*in partnership with YAFO Capital*

**Leading EIB advisor in Europe**

*Over 80 completed Healthcare & Life Sciences transactions (Professionals and Advisors)*

*8 regularly published Healthcare & Life Sciences reports*

## Healthcare & Life Sciences Team



**Dr. Alexandra Goll**  
*Advisor – Venture Capital*



**Dr. Axel Polack**  
*Advisor – Science & Technology*



**Claus Schalper**  
*Advisor – Corporate Affairs*



**Mathias Klozenbuecher**  
*Head of Healthcare & Life Sciences*



**Johannes Link**  
*Healthcare & Life Sciences Banking – Europe*



**Marco Vollnhals**  
*Healthcare & Life Sciences Banking – Europe*



**Enno Spillner**  
*Advisor – Capital Markets*



**Dr. Joachim M. Greuel**  
*Advisor – Valuations*



**Prof. Dr. Horst Domdey**  
*Advisor – Science & Technology*



**Zaid Maleh**  
*Healthcare & Life Sciences Banking – Dubai*



**Sean Jian, CFA**  
*Healthcare & Life Sciences Banking – China*



## Services

- ✓ Integrated Financial Modelling
- ✓ Investor / IR Roadshow
- ✓ Investor Screening
- ✓ Equity & Debt Fundraising
- ✓ Management Presentation
- ✓ Term Sheet Negotiation
- ✓ Post-Transaction Support
- ✓ Life Science Advisory Board
- ✓ Due Diligence Support
- ✓ Closing Assistance
- ✓ Financing Strategy Advisory
- ✓ IPO Execution Support

*(extract from service portfolio)*

## Our capital markets research feeds our proprietary investor database

### Data Collection

#### Healthcare & Life Sciences

##### Venture Capital Monitor – EU



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe*

##### Healthcare & Life Sciences Venture Capital Report



- *Venture Capital*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

##### Biotech Public Equity Monitor



- *Public Equity*
- *Biotech*
- *Focus on Europe*

##### Healthcare & Life Sciences IPO Report



- *IPOs*
- *Healthcare & Life Sciences*
- *Focus on Europe and the US*

##### Biotech Venture Capital Monitor – US



- *Venture Capital*
- *Life Sciences*
- *Focus on the US*

##### Biotech Licensing Monitor – China



- *Licensing*
- *Biotech*
- *Focus on Europe and Chinese licensors*

##### MedTech Public Equity Monitor



- *Public Equity*
- *MedTech*
- *Focus on Europe*

##### Healthcare & Life Sciences SPAC Monitor



- *SPACs*
- *Life Sciences*
- *Focus on US / Europe and US SPACs*


### Market Monitoring

#### Data Processing

- *Transaction data*
- *Investment preferences*

#### Proprietary Investor Database

- *Most comprehensive database*
- *> 1,300,000 data points*



#### Constant Data Enrichment

- *Ongoing investor communication*
- *Data validation*



#### Data-driven Investor Selection

1  
2  
3

- *Intelligent search algorithms*
- *Big data sequencing*

# Executive Summary

*The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals*

*More advanced, detailed and / or customized reports are available upon request*

## **FCF Healthcare & Life Sciences Venture Capital Monitor - Europe**

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European healthcare & life science industry

### **Scope**

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered healthcare & life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

*To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information*

## **Recipients**

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

## **Availability**

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"

## **Data**

All input data is provided by Pitchbook and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

*If you have questions, comments or ideas, please do not hesitate to contact us*


**EUROPEAN VENTURE CAPITAL TRANSACTIONS  
IN HEALTHCARE & LIFE SCIENCES**

OCTOBER 2023




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	Switzerland	208	F
3	Distalmotion	France	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	Denmark	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	Germany	221	33
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	137	10
4	Forbion	Denmark	131	10
5	Jeito	France	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
1	31/10/2023	Womed	FRA	MedTech	Women's Health / Undisclosed	Developer of medical devices designed to improve fertility and restore the uterus for pregnancy.	-	5	5	The company raised EUR 5 million of venture funding on October 31, 2023.
2	31/10/2023	Onena Medicines	CHE	Biotech / Pharma	Oncology / Developing	Developer of antibodies medicines intended for the treatment of advanced cancers by reprogramming cancer cells.	-	4	4	The company raised CHF 3.7 million of venture funding on October 31, 2023. The funds will be used to accelerate the development of its growing Dual SMAD Inhibiting Protein (DSIP) modulating antibody portfolio.
3	31/10/2023	Sigrid Therapeutics	SWE	MedTech	Medical Device / Undisclosed	Developer of a medical device designed for lowering blood sugar in prediabetics.	-	4	4	The company raised \$4 million of venture funding on October 31, 2023. The funds will be used in accelerating the commercialisation of the company across diverse markets, including medical devices, food supplements, veterinary, and oral health.
4	31/10/2023	Healper	DNK	HealthTech	Mental Health Platform / On market	Operator of a mental health platform intended to find a good psychologist to cope with anxiety and stress.	-	< 1	< 1	The company raised DKK 3 million of venture funding through a combination of debt and equity on October 31, 2023. The funds will be used to set the course for more organic growth.
5	30/10/2023	Enterome	FRA	Biotech / Pharma	Oncology / Phase II	Developer of pharmaceuticals and diagnostics tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types.	-	3	3	The company received EUR 3 million in funding on October 30, 2023. The funds will be used to propel the Company's ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymphoma (INHL).
6	30/10/2023	Gate2Brain	ESP	Biotech / Pharma	Drug Delivery Platform / Pre-clinic	Developer of a novel technology platform designed for the delivery of therapeutics across biological barriers.	-	< 1	< 1	The company received EUR 1,500 in funding in the form of a grant on October 30, 2023. The funds will be used to advance the development of the revolutionary technology for drug administration to the brain.
7	27/10/2023	A4Cell	ESP	Healthcare Services	Monitoring Device / On market	Developer of a cell monitoring device designed to study living single-cell behavior and general information.	-	3	3	The company raised EUR 3 million of venture funding on October 27, 2023. The funds will be used for intensifying research and development efforts, expanding the team of researchers and engineers, and accelerating the production of cutting-edge technologies.
8	27/10/2023	Galeneo	ESP	HealthTech	Digital Health Platform / On market	Operating of a healthcare management platform intended to transform the delivery of primary home healthcare.	-	1	1	The company raised EUR 1 million of venture funding on October 27, 2023. The funds will be used for consolidating the B2B model for clinics and hospitals and seeking to increase its participation within the public and pharmaceutical sectors


Source: PitchBook as of 15-11-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	CH	208	F
3	Distalmotion	FR	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	DK	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	221	33
2	Revival Healthcare Capital	US	142	2
3	Gilde Healthcare Partners	DK	137	10
4	Forbion	DK	131	10
5	Jeito	FR	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
9	27/10/2023	Teleradius	POL	HealthTech	Analysis Platform / Undisclosed	Developer of innovative radiology tools designed to streamline radiological descriptions and expedite patient diagnoses.	-	< 1	< 1	The company raised PLN 1.5 million of venture funding on October 27, 2023. The funds will be used to improve access to diagnostic imaging services and supporting health facilities and patients in Poland.
10	26/10/2023	Irisbond	ESP	MedTech	Disabled Assistance Device / On market	Developer of a system-based eye-tracker designed for humans to communicate based on precision eye-tracking technology.	-	2	2	The company raised EUR 2 million of venture funding on October 26, 2023. The funds will be used to promote the company's eye-tracking in the healthcare field and its expansion in the USA.
11	26/10/2023	Loop Dee Science	FRA	MedTech	Diagnostic Testing / On market	Developer of detection kits designed to make molecular biology diagnostics accessible to people.	-	2	2	The company raised EUR 1.8 million of venture funding on October 26, 2023. The funds will be used to start marketing its products in the French and European markets.
12	25/10/2023	ImmuONE	GBR	Biotech / Pharma	Other / On market	Operator of a biotech company intended to provide in vitro cell culture services for safety assessment.	-	2	2	The company raised GBP 2 million of venture funding on October 25, 2023. The funds will be used to move into new headquarters in Milton Keynes, and new laboratories in Stevenage, to meet the growing demand and additionally expand capacity, continue research and development, grow the team, and create six new jobs.
13	24/10/2023	Vitadio	CZE	HealthTech	Medical Platform / On Market	Developer of a medical platform intended to offer clinically-validated digital therapeutics for type 2 diabetes.	-	3	3	The company raised EUR 3 million of venture funding on October 24, 2023. The funds will be used to further expand its platform as well as add new therapies such as enabling people to live free of chronic conditions.
14	24/10/2023	Scope Biosciences	NLD	Biotech / Pharma	Diagnostics Platform / On market	Operator of a molecular diagnostics platform intended to provide innovative and accessible CRISPR-Cas-based tests for infectious diseases and genetic traits.	-	< 1	< 1	The company raised EUR 500,000 of venture funding on October 24, 2023. The funds will be used to accelerate the introduction of its first agricultural and horticultural tests to the market.
15	24/10/2023	Silbo	FRA	MedTech	Patient Management Platform / On market	Operator of a patient flow management platform intended to optimize healthcare operations.	-	< 1	2	The company raised EUR 346,865 of venture funding on October 24, 2023, putting the company's pre-money valuation at EUR 2.51 million. The funds will be used to continue to structure the company, to further increase investments in R&D and initiate an international approach.
16	24/10/2023	WeNurse	CHE	HealthTech	Other / On market	Developer of a nursing platform intended for the real-time availability of nursing staff.	-	< 1	< 1	The company received \$50,000 in funding in the form of a grant on October 24, 2023.

Source: PitchBook as of 15-11-2023; FCF Equity Research


Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)




### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	CH	208	F
3	Distalmotion	FR	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	DK	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	221	33
2	Revival Healthcare Capital	US	142	2
3	Gilde Healthcare Partners	FR	137	10
4	Forbion	FR	131	10
5	Jeito	FR	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
17	20/10/2023	X-Bolt	IRL	MedTech	Orthopedics / On market	Developer and legal manufacturer of trauma orthopedic devices designed for internal bone fixation.	A	3	3	The company raised EUR 3 million of Series A venture funding on October 20, 2023.
18	18/10/2023	Perseus Biomics	BEL	MedTech	Microbiome Profiling / On market	Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life.	B	6	8	The company raised \$6 million of Series B venture funding on October 18, 2023, putting the company's pre-money valuation at \$34 million.
19	18/10/2023	Dania Therapeutics	DNK	Biotech / Pharma	Oncology / Developing	Developer of medicinal products designed for cancer and other related activities.	-	2	2	The company raised DKK 15 million of venture funding on October 18, 2023.
20	17/10/2023	Poppins (Healthcare Technology Systems)	FRA	HealthTech	Learning Disorders / Undisclosed	Developer of a learning digital therapeutic technology designed to improve cognitive function in children having learning disorders.	A	8	8	The company raised EUR 8 million of venture funding on October 17, 2023.
21	17/10/2023	Carbometrics	GBR	HealthTech	Metabolic Disorders / Undisclosed	Developer of a glucose-binding molecule platform intended to help people with diabetes to live more normal and longer lives.	-	5	13	The company raised GBP 4.10 million of venture funding on October 17, 2023, putting the company's pre-money valuation at GBP 30.37 million.
22	17/10/2023	Homed-IQ	NLD	MedTech	Health Testing / On market	Retailer of health testing kits intended to help find the easiest way to track self-health.	-	1	1	The company raised EUR 1 million of venture funding on October 17, 2023. The funds will be used to realize company's vision of accessible medical diagnostics further.
23	16/10/2023	Deciphex	IRL	HealthTech	Medical Software / Undisclosed	Developer of medical software applications designed for preclinical pathology.	-	10	10	The company raised EUR 10 million of venture funding in the form of convertible debt on October 16, 2023. The funds will be used to to expand company's services and grow its team.
24	13/10/2023	Frontwave Imaging	ESP	HealthTech	Imaging Device / Undisclosed	Developer of medical device designed to offer quality 3D ultrasound images of the breast to improve diagnostics.	-	3	3	The company raised EUR 3 million of venture funding on October 13, 2023.


Source: PitchBook as of 15-11-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	CH	208	F
3	Distalmotion	FR	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	DK	130	C


#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	221	33
2	Revival Healthcare Capital	US	142	2
3	Gilde Healthcare Partners	FR	137	10
4	Forbion	FR	131	10
5	Jeito	FR	129	9


#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
25	12/10/2023	Synerkine Pharma	NLD	Biotech / Pharma	Pain Treatment / Developing	Developer of fusion proteins designed to help in the treatment of inflammatory and neuropathic pain.	A	12	12	The company raised EUR 12.1 million of Series A venture funding on October 12, 2023. The funds will be used to accelerate the development of Synerkine Pharma's lead asset SK-01, a therapeutically active cytokine fusion protein, into clinical studies in complex regional pain syndrome (CRPS), a severe chronic pain indication.
26	12/10/2023	Tilak Healthcare	FRA	HealthTech	Chronic Diseases/ On market	Developer of mobile medical games designed to transform chronic disease monitoring with fun and engaging games.	-	10	10	The company raised EUR 10 million of venture funding on October 12, 2023. The funds will be used to accelerate its deployment in France and internationally.
27	12/10/2023	Cirdan	GBR	HealthTech	Other / On market	Developer of healthcare informatics software designed to offer imaging technology to accelerate and enhance diagnosis.	-	3	3	The company raised GBP 2.3 million of venture funding on October 12, 2023. The funds will be used to expand its ability to grow and improve the way it onboards new customers and expand the company's business operations.
28	12/10/2023	Occuity	GBR	MedTech	Other / Developing	Developer of non-contact optical instruments designed for use in optometry or other optical measurements as well as disease diagnosis and monitoring through the eye.	B	2	13	The company raised GBP 2.11 million of Series B venture funding on October 12, 2023, putting the company's pre-money valuation at GBP 22.17 million.
29	12/10/2023	MLA Diagnostics	NLD	MedTech	Oncology / Developing	Developer of a prognostic test kit designed to diagnose early-stage melanoma.	A	< 1	< 1	The company raised EUR 550,000 of Series A venture funding on October 12, 2023.
30	11/10/2023	AgomAb Therapeutics	BEL	Biotech / Pharma	Other / Phase I	Developer of agonistic antibodies designed to help in the regeneration of damaged tissues.	C	94	94	The company raised \$100 million of Series C venture funding on October 11, 2023. The funds will be used for clinical Phase 2 stage lead candidate AGMB-129 for Fibrotensing Crohn's Disease and the development of a highly innovative pipeline of anti-fibrotic and regenerative therapies and also for strategic expansion of the organization and fund general corporate purposes.
31	11/10/2023	MinervaX	DNK	Biotech / Pharma	Infectious Diseases / Phase II	Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threatening infections caused by group B streptococcus.	-	54	54	The company raised EUR 54 million of venture funding on October 11, 2023. The funds will be used to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus.
32	11/10/2023	Lustre ClearSkin	GBR	MedTech	Dermatology / On market	Developer of wearable light products designed to treat specific dermatological conditions.	-	1	20	The company raised GBP 970,436 of venture funding on October 11, 2023, putting the company's pre-money valuation at GBP 2.70 million.

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	Switzerland	208	F
3	Distalmotion	France	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	Denmark	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	Germany	221	33
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	137	10
4	Forbion	Denmark	131	10
5	Jeito	France	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
33	11/10/2023	GoSense	FRA	MedTech	Disabled Assistance Device / On market	Developer of sensory enhancement technologies designed for visually impaired persons.	-	1	1	The company raised EUR 1 million of equity crowdfunding via Vita.co on October 11, 2023. Ophtabus and PhiTrust Impact Investors also participated in this round. The funds will be used to launch Rangio in Germany.
34	11/10/2023	Curada	GBR	HealthTech	Telehealth Platform / On market	Developer of a telehealth platform designed to cure alcohol disorder.	-	<1	<1	The company received \$20,000 in funding on October 11, 2023. Putting the company's pre-money valuation at \$313,300.
35	11/10/2023	Mindflow Health	GBR	HealthTech	Neurology / On market	Operator of a digital brain health clinic designed to prevent dementia at scale.	-	<1	<1	The company received \$20,000 in funding on October 11, 2023. Putting the company's pre-money valuation at \$313,300.
36	10/10/2023	RDS	FRA	MedTech	Monitoring Device / On market	Manufacturer of a wearable health-tracking device intended to continuously measure vital sign parameters.	Seed	13	13	The company raised EUR 13 million of venture funding on October 10, 2023. The funds will be used for development and launch of product.
37	09/10/2023	LimmaTech Biologics	CHE	Biotech / Pharma	Infectious Diseases / Phase II	Operator of a clinical-stage biopharmaceutical firm focused on the prevention of life-threatening diseases.	A	35	35	The company raised \$37 million of Series A venture funding on October 9, 2023. The funds will be used to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhoea.
38	09/10/2023	Pixelgen Technologies	SWE	Biotech / Pharma	Analysis Platform / On market	Developer of bio-analytical tools designed for biomedical research and diagnostics.	A	7	7	The company raised an estimated \$7.3 million of venture funding on October 9, 2023. The funds will be used to support the commercial expansion of Pixelgen's recently launched spatial proteomics tool for analyzing cell surface proteins on single cells to transform drug discovery and basic science.
39	09/10/2023	Renalyse	ESP	MedTech	Health Monitoring Platform / On market	Developer of a healthcare technology platform designed to monitor health.	-	1	1	The company raised EUR 1 million of venture funding on October 9, 2023. The funds will be allocated towards the industrialization and certification of the company's Chronic Kidney Disease diagnostic and monitoring device.
40	09/10/2023	OmicsChart	DEU	HealthTech	Discovery Platform / On market	Developer of a cancer data and biomarker discovery platform designed to revolutionize how precision oncology data is shared.	-	<1	<1	The company received \$20,000 in funding on October 9, 2023, putting company's pre-money valuation at \$313,300.

Source: PitchBook as of 15-11-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

# European Venture Capital Transactions in Healthcare & Life Sciences


## October 2023

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	CH	208	F
3	Distalmotion	FR	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	DK	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	BE	221	33
2	Revival Healthcare Capital	US	142	2
3	Gilde Healthcare Partners	DK	137	10
4	Forbion	DK	131	10
5	Jeito	FR	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
41	06/10/2023	Nabla	FRA	HealthTech	Care Management Platform / Undisclosed	Developer of a machine learning-powered care platform designed to identify personalized actionable trends to improve health.	-	22	22	The company raised an estimated \$23 million of venture funding on October 6, 2023.
42	05/10/2023	Laminar Pharma	ESP	Biotech / Pharma	Other / Phase III	Operator of a biopharmaceutical company intended to focus on the discovery, rational design, and initial clinical development of new MLT-based drugs.	-	9	9	The company raised EUR 8.8 million of venture funding on October 5, 2023. The funds will be used to achieve new improvements to the drug.
43	05/10/2023	Inovedis	DEU	MedTech	Surgical Device / Undisclosed	Developer of a surgical device designed to treat shoulder-based injuries in better ways.	A	4	4	The company raised \$4 million of Series A venture funding on October 5, 2023.
44	04/10/2023	Shorla Oncology	IRL	Biotech / Pharma	Oncology / Developing	Developer of oncology medicines intended to bring accessible, affordable, and life-saving treatments for patients with pediatric cancers.	B	33	33	The company raised \$35 million of Series B venture funding on October 4, 2023. The funds will be used to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication
45	04/10/2023	Mytos	GBR	MedTech	Cell Manufacturing Platform / Undisclosed	Developer of a fully automated cell manufacturing platform designed to automate human cell production for pharma and biotech businesses.	-	17	17	The company raised \$18.00 million of venture funding on October 4, 2023.
46	02/10/2023	AstronauTx	GBR	Biotech / Pharma	Central Nervous System / Developing	Operator of a biotechnology platform intended for the treatment of Alzheimer's disease and other neurodegenerative diseases.	A	54	54	The company raised GBP 48 million of Series A venture funding on October 2, 2023. The funds will be used to advance the company's portfolio of small-molecule drugs, including a clinical study in patients with Alzheimer's disease for the lead program.
47	02/10/2023	Kranus Health	DEU	HealthTech	Male Health / On market	Operator of a digital health platform intended to help men eliminate the effects of erectile dysfunction and nausea.	A	15	15	The company raised EUR 15 million of Series A venture funding on October 2, 2023. The funds will be used to scale Kranus Health's therapies across multiple further countries.
48	02/10/2023	Follow (Enterprise Systems (Healthcare))	FRA	HealthTech	Digital Health Software / Developing	Developer of a healthcare application intended to manage health consultations and monitor patients.	-	4	4	The company raised EUR 4 million of venture funding on October 2, 2023.


Source: PitchBook as of 15-11-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

### Overview (YTD)


#### Cumulative Financing Volume (EURm)




#### Subsectors




#### Indications<sup>1</sup>



#### Top Company Origins



#### Top Investor Origins



#### Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Apollo Therapeutics	Switzerland	208	F
3	Distalmotion	France	142	C
4	CMR Surgical	UK	142	D
5	Amolyt Pharma	Denmark	130	C

#### Top 5 Investors

#	Investor	HQ	Deal Volume <sup>2</sup>	# of Deals
1	EIC Fund	Belgium	221	33
2	Revival Healthcare Capital	USA	142	2
3	Gilde Healthcare Partners	Denmark	137	10
4	Forbion	Denmark	131	10
5	Jeito	France	129	9

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
49	02/10/2023	Le Comptoir Des Pharmacies	FRA	HealthTech	Pharmacy Management Platform / Developing	Developer of an inventory management platform designed to facilitate the management of stocks between pharmacies.	-	4	4	The company raised EUR 3.5 million of venture funding on October 2, 2023.
50	02/10/2023	MolEndoTech	GBR	Biotech / Pharma	Pathogen Testing Device / On market	Developer of a microbiological testing equipment designed to detect specific pathogenic bacteria and improve water quality.	-	1	2	The company raised GBP 1.23 million of venture funding on October 2, 2023, putting the company's pre-money valuation at GBP 4.57 million. The funds will be used by the company for the commercialization and development of its product Bacterisk+, an easy-to-use, portable and rapid test to monitor and detect pathogens found in water.
51	02/10/2023	HeroSupport	CHE	MedTech	Medical Care Device / Undisclosed	Manufacturer of medical immobilization devices intended to offer patient comfort in clinical practice.	-	< 1	< 1	The company received CHF 150,000 in funding in the form of convertible debt on October 2, 2023. The funds will be used to set up 3D printing lab and complete certification to work with their first customers.
52	01/10/2023	ADmit Therapeutics	ESP	MedTech	Central Nervous System / Developing	Developer of a medical diagnostic test intended to come up with early detection for Alzheimer's disease.	-	5	5	The company raised EUR 5.4 million of venture funding on October 2023. The funds will be used to obtain CE marking and FDA approval for the commercialization of MAP-AD in Europe and the United States.
53	01/10/2023	GitLife Biotech	GBR	Biotech / Pharma	Biomedical Platform / On market	Developer of a biotechnology company designed to protect the development of scientists in a structured, centralised format.	-	< 1	< 1	The company raised GBP 500,000 of venture funding on October 1, 2023, putting the company's pre-money valuation at GBP 2.5 million.

Source: PitchBook as of 15-11-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

<sup>1</sup>Only includes biotechnology and pharmaceutical deals; <sup>2</sup>Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

# Contact Details & Disclaimer



## FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany  
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299  
info@fcf.de ▪ www.fcf.de

### Arno Fuchs

*Chief Executive Officer*

P: +49 (89) 206 0409-100  
M: +49 (172) 863 6777  
arno.fuchs@fcf.de

### Mathias Klozenbuecher

*Managing Director*

P: +49 (89) 2060 409-123  
M: +49 (174) 301 1846  
mathias.klozenbuecher@fcf.de

### Johannes Link

*Associate*

P: +49 (89) 206 0409-150  
M: +49 (172) 839 5746  
johannes.link@fcf.de

### Marco Vollnhals

*Intern*

P: +49 (89) 206 0409-127  
marco.vollnhals@fcf.de

## DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST